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Abstract
Background: The phosphoethanolamine methyltransferase, PfPMT, of the human malaria parasite Plasmodium
falciparum, a member of a newly identified family of phosphoethanolamine methyltransferases (PMT) found solely
in some protozoa, nematodes, frogs, and plants, is involved in the synthesis of the major membrane phospholipid,
phosphatidylcholine. PMT enzymes catalyze a three-step S-adenosylmethionine-dependent methylation of the
nitrogen atom of phosphoethanolamine to form phosphocholine. In P. falciparum, this activity is a limiting step in
the pathway of synthesis of phosphatidylcholine from serine and plays an important role in the development,
replication and survival of the parasite within human red blood cells.
Results: We have employed an enzyme-coupled methylation assay to screen for potential inhibitors of PfPMT. In
addition to hexadecyltrimethylammonium, previously known to inhibit PfPMT, two compounds
dodecyltrimethylammonium and amodiaquine were also found to inhibit PfPMT activity in vitro. Interestingly,
PfPMT activity was not inhibited by the amodiaquine analog, chloroquine, or other aminoquinolines, amino
alcohols, or histamine methyltransferase inhibitors. Using yeast as a surrogate system we found that unlike wild-
type cells, yeast mutants that rely on PfPMT for survival were sensitive to amodiaquine, and their
phosphatidylcholine biosynthesis was inhibited by this compound. Furthermore NMR titration studies to
characterize the interaction between amoidaquine and PfPMT demonstrated a specific and concentration
dependent binding of the compound to the enzyme.
Conclusion: The identification of amodiaquine as an inhibitor of PfPMT in vitro and in yeast, and the biophysical
evidence for the specific interaction of the compound with the enzyme will set the stage for the development of
analogs of this drug that specifically inhibit this enzyme and possibly other PMTs.
Background
Malaria is one of the most important parasitic diseases
worldwide responsible for over 200 million clinical cases
with an estimated 1 million deaths annually [1]. Malaria
is caused by intraerythrocytic protozoan parasites of the
genus Plasmodium. Of the five species infective to
humans, Plasmodium falciparum is responsible for the
highest level of mortality and morbidity [1]. The lack of
an effective vaccine and the rapid rise of resistance to
the most potent and affordable antimalarial drugs cre-
ates an urgent need for new therapies to prevent malaria
pathogenesis and transmission. Novel strategies are now
necessary to limit the appearance and spread of drug
resistant malaria strains. One such a strategy involves
targeting metabolic pathways proven to play an essential
function in the parasite’s infection and transmission.
Recent studies indicate that the metabolic pathways for
the synthesis of the major P. falciparum phospholipids
are excellent targets for the development of lipid-based
antimalarial therapies [2-4].
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esis of phosphatidylcholine during the intraerythrocytic
life cycle of the parasite occurs via two pathways, the
serine-decarboxylase phosphoethanolemine methyltrans-
ferase (SDPM) pathway and the CDP-choline pathway
[2-4]. The SDPM pathway uses serine either transported
from human serum or resulting from degradation of
host hemoglobin as a starting precursor. Serine is first
decarboxylated by a parasite serine decarboxylase to
form ethanolamine. Ethanolamine is next phosphory-
lated by a parasite ethanolamine kinase to form phos-
phoethanolamine (P-EA). A parasite S-
adenosylmethionine (SAM)-dependent methyltransfer-
ase, PfPMT, catalyzes a three-step methylation of P-EA
to form phosphocholine [3,5,6], which is converted into
phosphatidylcholine (PtdCho) via the activity of two
parasite enzymes PfCCT and PfCEPT. The CDP-choline
pathway uses choline transported from the host as a
precursor. Choline is phosphorylated by a parasite cho-
line kinase PfCK to phosphocholine, which is subse-
q u e n t l ym o d i f i e db yP f C C Tt oC D P - c h o l i n ea n db y
PfCEPT to PtdCho.
The 266 amino acid PfPMT is a member of a new
class of SAM-dependent methyltransferases that acts on
P-EA [3]. Homologs of this enzyme are found in plants,
nematodes, frogs, fish and other protozoa but not in
mammals [7-11]. While phosphoethanolamine methyl-
transferases (PEAMT) share significant homology in
their primary structure, the organization of their cataly-
tic domains differ. The plant PEAMTs have two tandem
catalytic domains, with the N-terminal domain catalyz-
ing the methylation of P-EA to monomethylpho-
sphoethanolamine and the C-terminal domain acting in
the last two methylation reactions to form phosphocho-
line [7,9,10]. C. elegans expresses two PEAMT enzymes
each containing only one methyltransferase domain
located at either the N-terminus of the protein, in the
case of Pmt1, or at the C-terminus of the protein in
Pmt2 [8,11]. Pmt1 catalyzes only the first methylation
reaction, whereas Pmt2 catalyzes the last two methyla-
tion reactions. The Plasmodium PfPMT is only half the
size of the plant and nematode proteins, possesses a sin-
gle catalytic domain, and catalyzes all three methylation
steps [3]. No crystal or solution structures of these
enzymes are available.
Confocal and immunoelectron microscopy studies
have shown that PfPMT is expressed in the Golgi appa-
ratus of the parasite [12]. Biochemical and genetic ana-
lyses using yeast as a surrogate system allowed
identification of residues in this enzyme that play a criti-
cal role in PfPMT catalysis and substrate binding [6].
The finding that PfPMT has no homologs in mamma-
lian databases suggested that this protein could be an
ideal target for the development of novel antimalarial
inhibitors targeting lipid metabolism. Interestingly, bio-
chemical studies revealed that PfPMT activity was inhib-
ited by S-adenosyl homocysteine (SAH) as well as by
phosphocholine and its analog and anticancer drug, hex-
adecylphosphocholine (Miltefosine) [3]. When tested
against P. falciparum, hexadecylphosphocholine was
found to inhibit the growth of the parasite within
human erythrocytes with 50% inhibitory concentrations
in the low micromolar range [3]. Genetic studies in P.
falciparum demonstrated that PfPMT plays an impor-
tant role during the intraerythrocytic life cycle of the
parasite [13]. Parasites lacking PfPMT display severe
alterations in development, replication and survival
within human red blood cells [13]. These defects were
only partially complemented by choline
supplementation.
Here we provide biochemical and biophysical data
indicating that PfPMT activity is inhibited by amodia-
quine (AQ). Using yeast as a surrogate system we show
that AQ inhibits PfPMT activity and blocks PtdCho
biosynthesis.
Methods
Materials
S-adenosylmethionine (SAM), S-adenosylhomocysteine
(SAH), Phosphoethanolamine (P-Etn), Cholorquine
(CQ), Amodiaquine (AQ), Hexadecyltrimethylammo-
nium bromide (HDTA), Dodecyltrimethylammonium
bromide (DDTA), 2,3-Dichloro- a- methylbenzylamine
(DCMB), Chlorpromazine, and Diphenhydramine were
purchased from Sigma. Miltefosine (HePC) was pur-
chased from Cayman chemicals. SKF91488 and Tacrine
were purchased from Tocris Bioscience. Recombinant
SAH nucleosidase (SAHN) was purified from an E. coli
strain generously given by K. Cornell (VAMC, Portland,
OR, USA), as previously described [14].
Expression and purification of recombinant PfPMT and
BsAda
P. falciparum PfPMT cDNA cloned in the expression
v e c t o rp E T - 1 5 ba n de x p r e s s e di nE. coli BL21-Codon-
Plus strain was purified as described earlier [3,6].
Expression strains were grown at 37°C in LB medium
containing 100 μg/ml ampicillin and 35 μg/ml chloram-
phenicol. A 1 L culture of E. coli was grown until an
A600 ~ 0.6, and PfPMT expression was induced by addi-
tion of 1 mM isopropyl-b-D-thiogalactopyranosidase
(IPTG). The cells were harvested 3 h after induction by
centrifugation, and resuspended in 25 ml lysis buffer (50
mM NaH2PO4,3 0 0m MN a C l ,1 0m Mi m i d a z o l e ,p H
8.0) containing a protease inhibitor cocktail (complete
Mini, EDTA-free, Roche Diagnostics). The cells were
lysed by sonication using 10 s discontinuous cycles for
three minutes on ice, and the cell debris and unbroken
cells were removed by centrifugation at 10,000 rpm at
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a 5 ml Ni-NTA (Qiagen) column pre-equilibrated in
lysis buffer. The column was subsequently washed with
40 ml of buffer (50 mM NaH2PO4,3 0 0m MN a C l ,2 0
mM imidazole, pH 8.0) and the protein was eluted from
the column in a single 15 ml fraction of buffer (50 mM
NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0).
The protein was incubated at 4°C for 1 h in the pre-
sence of 2 mM Na2EDTA, followed by dialysis and con-
centration against HEPES (N-(2-hydroxyethyl)-
piperazine-N’-2-ethanesulfonic acid) assay buffer (100
mM HEPES-KOH, pH 7.5) using Amicon Ultra centrifu-
gal filter devices. The purity of the recombinant enzyme
was examined by SDS-PAGE, and the protein concen-
tration was measured by the method of Bradford using
bovine serum albumin as a standard.
The gene encoding Bacillus subtilis adenine deaminase
(BsAda) was amplified from genomic DNA by PCR and
ligated into a pET15b plasmid vector between XhoI and
BamHI sites to yield an N-terminal 6His-epitope-tagged
encoding construct. The resulting plasmid was then
transformed into E. coli BL21-CodonPlus strain for
enzyme expression. The purification protocol for BsAda
is similar to PfPMT purification except that the 1 hr
incubation step with 2 mM Na2EDTA was omitted.
PfPMT enzyme-coupled spectrophotometric assay
Assays were performed in 96-well UV-transparent plates
(acrylic, non-sterile, Costar) at 37°C. Manganese sulfate
(MnSO4) was added to a final concentration of 1 mM
[15]. The assay mixture in 1X HEPES assay buffer (100
mM HEPES-KOH, pH 7.5) contained 200 μMS A M ,
200 μMP - E A ,1m MM n S O 4 ,0 . 5μMB s A d a ,4 . 7 2μM
SAHN and 2.5 μM PfPMT in a total volume of 200 μl.
A mixture without PfPMT was pre-incubated at 37°C
for 10 min and the reaction was initiated with the addi-
tion of PfPMT. Absorbance at 265 nm was continuously
r e c o r d e dw i t haU V ,v i s i b l ep l a t e - r e a d e r( S y n e r g yH T
Multi-Mode Microplate Reader, Biotek) under kinetic
mode. A negative control containing all the reaction
components except for PfPMT was conducted on the
same plate as the experimental reactions. The absor-
bance value of the control reaction was subtracted from
the experimental absorbance values to eliminate the
background signal.
Inhibition studies
All inhibitor containing stock solutions were prepared in
H2O, except for HDTA, which was prepared in DMSO.
The final concentration of DMSO in the assays did not
exceed 10%. Control experiments containing reaction
components and inhibitors were performed in the
absence of PfPMT to quantify the intrinsic absorbance
of inhibitors at 265 nm. These inhibitors were added
before the pre-incubation step. The absorbance at 265
nm for a PfPMT assay without inhibitor was assigned as
100% PfPMT activity. The absorbance values obtained
for the various inhibitor concentrations were then con-
verted into a PfPMT activity percentage and plotted
against inhibitor concentration. Control experiments
were performed to ensure that the inhibitors did not
affect the coupling enzymes. To measure coupling
enzyme sensitivity to inhibitors, 100 μMS A Hw a su s e d
in place of SAM and P-EA in a 200 μl reaction in the
presence of the inhibitor at the highest concentration
used in PfPMT assay. For Ki determination enzymatic
assays were performed with increasing concentrations of
P-EA (50, 75, 100, 125, 150, 175, and 200 μM), 200 μM
SAM, 1 mM MnSO4,0 . 5μMB s A d a ,4 . 7 2μMS A H N
and 2.5 μM PfPMT in a HEPES assay buffer, along with
the inhibitor AQ (0, 2, 4, 10 μM). A reciprocal plot was
generated from the absorbance readings at 265 nm ver-
sus the P-EA concentrations for each concentration of
AQ. The fitted line was extrapolated through the X axis
to determine the estimated Ki.
Yeast growth assays
BY4741-pYes2.1 (wild-type) and mutant pem1Δpem2Δ-
pYes2.1-PfPMT yeast strains were pre-grown overnight
in uracil dropout synthetic galactose (4%) (SG-ura) med-
ium supplemented with 10 μM ethanolamine. The next
day, cells were harvested by centrifugation, washed twice
by resuspension in water and diluted to an A600 =0 . 0 0 5
in fresh SG-ura medium supplemented with 100 μM
ethanolamine, in the absence or presence of 10, 50, or
100 μM AQ. In a second set of experiments BY4741-
pYes2.1, pem1Δpem2Δ-pYes2.1 and pem1Δpem2Δ-
pYes2.1-PfPMT yeast strains were pre-grown overnight
in SG-ura medium supplemented with 2 mM ethanola-
mine. The next day, cells were harvested by centrifuga-
tion, washed by resuspension in water and diluted to an
A600 = 0.005 in fresh SG-ura medium lacking or supple-
mented with 1 mM choline in the presence of 0 or 200
μM AQ. In both sets of experiments, cells were grown
at 30°C and monitored by measuring the A600.
Yeast phospholipid analysis
pem1Δpem2Δ-pYes2.1 and pem1Δpem2Δ-pYes2.1-
PfPMT yeast strains were pre-grown in SG-ura med-
ium supplemented with 2 mM ethanolamine and 2
mM choline for 24 hours. The cells were harvested by
centrifugation, washed twice by resuspension in water
and diluted to an A600 =0 . 0 3i nt h eS G - u r am e d i u m
supplemented with 2 mM ethanolamine and grown
overnight to an A600 ~ 1.5. The cells were next har-
vested and the lipids extracted for two dimensional
thin layer chromatography using previously described
methods [5,6,16]. Lipids were stained with iodine
vapor and excised from the plate for quantification by
measuring phosphorus [17]. The results are shown as
the percentage of total phosphorus in each phospholi-
pid fraction.
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For NMR analysis, E. coli cells expressing 6his-epitope-
tagged PfPMT were grown in minimal medium (M9)
containing
15 N-ammonium chloride. The purification
of the recombinant enzyme followed the same proce-
dure described above except for the addition of a second
step of purification through a Superdex G75 gel filtra-
tion column in a buffer containing 50 mM HEPES, 50
mM NaCl, 5 mM DTT pH 6.9. The sample was concen-
trated and D2O was added to a final concentration of
7% (v/v). Amodiaquine stock solution was prepared in
ddH2O due to its low solubility. Serial dilutions were
prepared and 5 μl of the diluted samples were added to
the NMR sample containing 310 μM of purified PfPMT.
The AQ concentration was determined spectrophotome-
trically using extinction coefficients ε238 =2 7×1 0
3M
-
1cm
-1, ε251 =2 3×1 0
3M
-1cm
-1 and ε341 =1 9×1 0
3M
-
1cm
-1 [18]. The PfPMT concentration was determined
using the Edelhoch method [19-21]. Standard
1H-
15N
HSQC experiments were performed on
15N-labeled
PfPMT using a Varian Inova spectrometer operating at
a
1H frequency of 600 MHz. Data were processed using
nmrPipe [22] and analyzed using Sparky [23] or the
Rowland NMR Toolkit http://rnmrtk.uchc.edu.
Results
Coupling PfPMT activity to that of SAH nucleosidase and
adenine deaminase
To identify new inhibitors of PfPMT we adapted an
assay that couples the SAM-dependent transmethylation
of P-EA by PfPMT to the activity of two enzymes SAH
nucleosidase (SAHN) and adenine deaminase (BsAda)
(Fig. 1). PfPMT activity results in the production of
SAH and phosphocholine. The second enzyme SAHN
catalyzes the conversion of SAH into adenine and S-
ribosylhomocysteine. Adenine is converted into hypox-
anthine by the third enzyme, BsAda, thus producing a
decrease in absorbance at 265 nm (Fig. 2A). As shown
in Fig. 2A, addition of PfPMT resulted in a time-depen-
dent decrease in absorbance at 265 nm over a 30 min
period, whereas no change in absorbance occurred
when the enzyme was omitted. To demonstrate that the
measured rate of the coupled reactions was determined
solely by PfPMT, the enzyme activity was investigated in
the presence of a fixed PfPMT concentration but with
varying concentrations of SAHN or BsAda. As shown in
Fig. 2B, changing the concentrations of the coupling
enzymes had little or no effect on the overall rate of the
reactions. The effect of increasing concentrations of the
substrate P-EA and co-substrate SAM on PfPMT activ-
ity was also measured. PfPMT activity increased propor-
tionally to the concentration of these substrates, with
optimal activity measured when the substrate and co-
substrate concentrations were at 200 μM( F i g .2 C ) .
Higher concentrations of P-EA only slightly affected the
activity of the enzyme, whereas high SAM concentra-
tions inhibited the enzyme (data not shown). Under
optimal conditions, we also examined the effect of
PfPMT concentration on the rate of the reaction. As
shown in Fig. 2D, increasing the concentration of
PfPMT resulted in a proportional increase in activity
reflected by a decrease in absorbance over time. Above
this range, the enzyme activity started to deviate from
linearity (data not shown). We also tested the effect of
different buffers at pH 7, 7.5 and 8 on PfPMT activity.
These factors were found to have little effect on PfPMT
activity over time (Fig. 2E).
Application of the PfPMT spectrophotometric assay for
screening inhibitors of the enzyme
To assess the applicability of the enzyme-coupled assay
for screening inhibitors of PfPMT, the effects of some
known or potential inhibitors of this enzyme were
examined. As most drug screens are performed in the
presence of DMSO, we first tested the effect of this
agent on PfPMT activity. DMSO up to 10% had no
effect on PfPMT activity (data not shown). The hexade-
cylphosphocholine analog, miltefosine (HePC), was pre-
viously reported to inhibit PfPMT activity in vitro and
P. falciparum proliferation inside red blood cells with
similar efficacy [3]. Using the enzyme-coupled spectro-
photometric assay, HePC was found to inhibit PfPMT
activity with 100 μM of HePC reducing PfPMT activity
by ~60% and 150 μM of the compound resulting in a
complete loss of activity (Fig. 3A). As a control, an assay
in which PfPMT, SAM and P-EA were omitted and
replaced by their product SAH was performed in the
absence or presence of 200 μMo fH e P C .U n d e rt h e s e
conditions HePC had no effect on the production of
hypoxanthine over time, suggesting that neither SAHN
nor BsAda was inhibited by this compound. Two com-
pounds that are structurally related to HePC, hexadecyl-
trimethylammonium (HDTA) and
dodecyltrimethylammonium (DDTA) that are known to
have potent antimalarial activity in vitro and in vivo
[24-26] were also tested to determine their inhibitory
activity against PfPMT. HDTA was found to have an
inhibitory activity similar to that of HePC with ~50%
inhibition of PfPMT activity observed at 100 μMo ft h e
c o m p o u n d( F i g .3 B ) .D D T A ,h o w e v e r ,h a dn oe f f e c t
against the enzyme when used at concentrations of up
to 100 μM and only modest inhibitory activity at 500
μM, inhibiting 25% of PfPMT activity at this concentra-
tion (Fig. 3C).
Inhibition of PfPMT activity by amodiaquine in vitro and
in yeast
In order to identify possible lead inhibitors of PfPMT,
we examined the effect of drugs known to inhibit other
SAM-dependent methyltransferases. The 2,3-dichloro-
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human phenylethanolamine-N-methyltransferase
enzyme [27], which catalyses the terminal step in epi-
nephrine biosynthesis had no effect on PfPMT activity
even at 500 μM (Fig. 4A). Conversely, AQ, a known
inhibitor of histamine methyltransferases (HNMT) and a
potent antimalarial drug [28], was found to be a good
inhibitor of the enzyme with 60% inhibition at 5 μM
(Fig. 4B). None of these concentrations of AQ inhibited
the coupling enzymes used in the PfPMT assay (data
not shown). The finding that AQ inhibits PfPMT led us
to investigate the effect of four other HNMT inhibitors,
SKF91488, Tacrine, Chlorpromazine and Diphenhydra-
mine. None of these compounds had a significant effect
on PfPMT activity (Fig. 5A). Furthermore, none of the
compounds inhibited the growth of P. falciparum within
human erythrocytes at a concentration as high as 1 μM
(data not shown). The specificity of inhibition of PfPMT
by AQ was further demonstrated using its analog and
antimalarial drug, chloroquine (CQ). At 200 μMc o n -
centration, CQ had no effect on PfPMT activity (Fig.
5B). Other aminoquinolines and amino alcohols, quina-
crine, quinidine and quinine, known for their potent
antimalarial activity, had no effect on PfPMT activity at
concentrations up to 200 μM (Fig. 5B), suggesting that
AQ inhibition of PfPMT is specific. In order to examine
AQ inhibition of PfPMT in vivo we used yeast as a
surrogate system. Yeast is a particularly attractive system
for this analysis because, unlike P. falciparum,i ti sn o t
sensitive to AQ and lacks phosphoethanolamine methyl-
t r a n s f e r a s e s .W eh a v ep r e v i o u s l ys h o w nt h a tac o d o n -
optimized P. falciparum PfPMT gene complements the
choline auxotrophy of the yeast pem1Δpem2Δ mutant,
which lacks the two phospholipid methyltransferases,
Pem1p and Pem2p, and thus is unable to synthesize
PtdCho from PtdEtn [29,30]. In the complemented
strain, PfPMT restores PtdCho by providing phospho-
choline following P-EA transmethylation [5,6]. Examina-
tion of the growth of wild-type yeast cells in media
lacking or containing choline, and supplemented with
either 100 μMo r2μM ethanolamine (Fig. 6A and 6C),
and in the absence or presence of AQ demonstrated no
effect of this compound at concentrations up to 200
μM. Unlike pem1Δpem2Δ, which did not grow on med-
ium containing ethanolamine but lacking choline (Fig.
6D, curve 5 & 6), pem1Δpem2Δ strains complemented
with PfPMT grew on media lacking choline and their
growth rate was significantly influenced by the availabil-
ity of ethanolamine with the highest cell density reached
i nt h ep r e s e n c eo f2μM ethanolamine (Fig 6E, curve 5
& 6). Interestingly, the growth of pem1Δpem2Δ+PfPMT
was dramatically inhibited when AQ was added to the
culture medium (Fig. 6B). AQ inhibited the growth of
pem1Δpem2Δ+PfPMT strains in a concentration
Figure 1 Schematic description of the enzyme-coupled assay for measuring PfPMT activity. PfPMT catalyzes the conversion of 1 molecule
of P-EA and 3 molecules of SAM to form 1 molecule of phosphocholine and 3 molecules of SAH. SAH is hydrolyzed to adenine and S-
ribosylhomocysteine via SAHN nucleosidase. The deamination of adenine into hypoxanthine by adenine deaminase is associated with a decrease
in absorbance at 265 nm that can be monitored continuously using UV plate reader.
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Page 5 of 16Figure 2 Spectrophotometric analysis of phosphoethanolamine methyltransferase activity. (A) PfPMT-catalyzed methylation of P-EA.
Reaction mixtures contained 200 μM SAM, 200 μM P-EA, 1000 μM MnSO4, 0.5 μM BsAda, 4.72 μM SAHN and 0 μM (red) or 2.5 μM (blue) of
purified PfPMT enzyme in 100 mM HEPES assay buffer pH 7.5. The decrease in absorbance was monitored at 265 nm. The reactions components
were kept the same as stated above in panels B-E, except when noted. (B) Dependence of the rate of PfPMT-catalyzed reaction on different
concentrations of the coupling enzymes. Reactions contained BsAda 0.25 μM and SAHN 2.13 μM (orange), 0.5 μM BsAda, 4.72 μM SAHN (blue)
and without PfPMT (red), and BsAda 1 μM and SAHN 8.5 μM (green). (C) Dependence of the rate of PfPMT-catalyzed reaction on different
concentrations of SAM and P-EA. Reactions contained P-EA 50 μM and SAM 150 μM (orange), P-EA 100 μM and SAM 100 μM (black), p-Etn 150
μM and SAM 150 μM (green), P-EA 200 μM and SAM 200 μM (blue), and without PfPMT (red). (D) Effect of PfPMT concentration on its activity.
Reactions contained 0 μM PfPMT (red), 312.5 nM PfPMT (orange), 625 nM PfPMT (green), 1.25 μM PfPMT (black), and 2.5 μM (blue). (E) Effect of
the pH and buffer composition on PfPMT activity. Reaction mixtures contained 200 μM SAM, 200 μM P-EA, 1000 μM MnSO4, 0.5 μM BsAda, 4.72
μM SAHN and 0 μM (red) or 2.5 μM (black), of purified PfPMT enzyme in 100 mM HEPES assay buffer pH 7.5. Reactions also contained 100 mM
HEPES assay buffer pH 7 (green), and pH 8 (cyan), as well as 100 mM Tris-HCl assay buffer pH 7 (orange), pH 7.5 (purple), and pH 8 (yellow).
Results are representative of three independent experiments.
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by 76% in medium containing 100 μMe t h a n o l a m i n e
after 60 h (Fig. 6B). These results thus demonstrate a
direct inhibition of PfPMT by AQ in vivo.A d d i t i o no f
choline to the culture medium of pem1Δpem2Δ-PfPMT
cells resulted in complete resistance of these cells to AQ
(Fig. 6E, curve 7 & 8), suggesting that the inhibition of
growth was dependent on the essential function of
PfPMT for survival in the absence of exogenous choline.
As a control, the pem1Δpem2Δ mutant harboring an
empty vector did not grow in the absence of choline
and was resistant to AQ when choline was added (Fig.
6D).
To demonstrate that the inhibition of the growth of
pem1Δpem2Δ+PfPMT by AQ was due to the inhibition
of the synthesis of PtdCho from ethanolamine, the
synthesis of the major phospholipids PtdCho and PtdEtn
of yeast membranes was examined in the absence or
presence of AQ. Consistent with previous findings [5,6],
pem1Δpem2Δ cells harboring an empty vector produced
~3% of total phospholipid as PtdCho after 5 to 6 gen-
erations of growth in the choline deficient medium,
whereas those expressing PfPMT produced ~18%
PtdCho (Fig. 7). Addition of AQ to pem1Δpem2Δ cells
expressing PfPMT resulted in a concentration depen-
dent decrease in PtdCho levels with ~15% produced at
10 μM and ~5% produced at 200 μMA Q( F i g s .7 Aa n d
7B). These findings further demonstrate the specific
inhibition of PtdCho biosynthesis by this compound.
The depletion of PtdCho effected by genetic manipula-
tion or AQ treatment was partially compensated by
increased levels of PtdIns (Fig. 7).
Structural analysis of the interaction between PfPMT and
amodiaquine
Co-crystallization studies of human HNMT with AQ
indicated that two molecules of AQ were bound per
HNMT molecule [31]. One occupies the active site
pocket (Site 1; Figs. 8A and 8B) and was proposed to
competitively inhibit histamine binding, and the other
occupies a deep pocket representing an uncompetitive
component (Site 2; Figs. 8A and 8B) [31]. To character-
ize the nature of the inhibition of PfPMT by AQ and to
calculate the inhibition constant, PfPMT activity was
determined in the presence of increasing concentrations
of P-EA and increasing concentrations of the inhibitor.
These studies, however, did not allow distinction
between competitive and noncompetitive inhibition. To
further explore the interaction of AQ with PfPMT, we
performed NMR studies of the enzyme with varying
concentrations of AQ. The
1H-
15NH S Q Cs p e c t r a
revealed that of the 266 residues of PfPMT only about
20 residues showed a substantial change in chemical
shift as a function of increasing concentrations of AQ
(Fig. 9A and Additional file 1, Fig. S1). This demon-
strates direct and site-specific binding of AQ to PfPMT.
We were able to tentatively assign 9 of the 20 reso-
nances exhibiting shifts upon AQ binding. Mapped onto
corresponding residues in the HNMT structure (via
Figure 3 Inhibition of PfPMT by quaternary amines. Effect of increasing concentrations of hexadecylphosphocholine (HePC) (A),
hexadecyltrimethylammonium bromide (HDTA) (B) and dodecyltrimethylammonium bromide (DDTA) on PfPMT activity. The assay was
performed as described in Experimental Procedures. The data are the means +/- S.D. for three independent experiments. Statistically significant
data with a P < 0.05 is indicated with an asterisk.
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f o u n dt ob ep r o x i m a lt ot h et w oA Qb i n d i n gs i t e si n
HNMT. The 9th residue is proximal to residues that are
in contact with an AQ binding site. Nonspecific changes
involving many residues that are observed at high AQ
concentrations appear to reflect biophysical changes in
solution properties due to a concentrated co-solute.
We also performed NMR titrations using CQ (Fig.
9B). While the effects of CQ are similarly restricted to
about 20 residues, indicating site-specific binding, the
affinity of CQ for PfPMT is much lower than that of
AQ. Complete characterization of CQ binding by NMR
is hampered by nonspecific effects that begin to domi-
nate at concentrations above 3 mM (molar ratio of 10
in Fig. 9). Detailed comparison of the concentration
dependence of the chemical shifts for two residues, ten-
tatively assigned to Gly32 and Gly68, revealed the differ-
ence in the affinities of AQ and CQ for PfPMT. For
AQ, the chemical shift changes approached an asympto-
tic value approximately exponentially, consistent with all
binding sites occupied around a 3:1 molar ratio (Figs.
9C and 9D). In contrast, the chemical shifts of Gly32
and Gly68 changed only linearly up to a molar ratio of
10:1. The fact that the same residues are perturbed in
response to both AQ and CQ suggest that they interact
with the same site on PfPMT, but the different concen-
tration dependence suggests that the affinity of CQ for
PfPMT is at least an order of magnitude lower than that
of AQ.
Discussion
Methyltransferases represent a large group of enzymes
divided into 160 classes (EC 2.1.1.1 to EC2.1.1.160).
These enzymes catalyze the methylation of a large num-
ber of different substrates including DNA, RNAs, phos-
pholipids, fatty acids, inositol, phosphoethanolamine,
phenylethanolamine, tocopherol, catechol and histamine.
Although some methyl donor molecules such as S-
methylmethionine, betaine and folate can be used, the
majority of biologically active methyltransferase enzymes
utilize SAM as a methyl donor [32]. SAM-methyltrans-
ferases are recognized by the primary structure and
topology of the core fold containing the SAM binding
domain [32]. These enzymes play important functions in
various biological systems and have been linked to dif-
ferent human diseases such as Alzheimer’s disease,
attention deficit disorder and pre-eclampsia [33-35].
Phosphoethanolamine methyltransferases (PMTs) repre-
sent a recently identified class of enzymes found mostly
in plants, nematodes, frogs, fish and some species of
protozoa. Their absence in humans and the finding that
these enzymes play important physiological functions
make them good targets for the development of novel
inhibitors to treat worm and protozoan parasitic
Figure 4 Amodiaquine inhibits purified PfPMT activity. Effect of increasing concentrations of DCMB (A) and amodiaquine (AQ) (B) on PfPMT
activity. The assay was performed as described in Methods. The data are the means +/- S.D. for three independent experiments. Statistically
significant data with a P < 0.01 is indicated with an asterisk.
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Page 8 of 16diseases [3,8,11]. The use of radiolabeledS A Mt oa s s a y
PMTs in vitro makes it difficult to perform large-scale
screenings of available chemical libraries to search for
i n h i b i t o r so ft h e s ee n z y m e s .H e r ew eh a v em o d i f i e da
continuous coupled assay previously described by Dor-
gan et al [36] for the rat arginine N-methyltransferase 1
(PRMT1) to measure PfPMT activity in vitro and
demonstrated its feasibility for drug inhibition assays
using HePC, which was previously shown to inhibit
PfPMT with a radioactivity-based assay [3]. In this
report, PfPMT activity was inhibited ~60% at a concen-
tration of 100 μMo fH e P Ca n d1 5 0μMo ft h i s
compound resulted in a complete loss of activity. The
enzyme-coupled assay was also useful in identifying
HDTA as an inhibitor of PfPMT activity. HDTA was
found to have an inhibitory activity similar to that of
HePC with ~50% inhibition of PfPMT activity observed
at 100 μM of the compound. HDTA inhibits the growth
of P. falciparum in culture with an IC50 of 2.1 μM[ 2 4 ] .
Using this assay we have also identified AQ as an inhibi-
tor of PfPMT. In addition to its antimalarial activity, AQ
is also known as a potent inhibitor of the human hista-
mine N-methyltransferase (HNMT) [31]. Other more
potent inhibitors of HNMT such as SKF91488, tacrine,
Figure 5 Effect of HNMT inhibitors and antimalarial aminoquinolines and amino alcohols on PfPMT activity.( A )E f f e c to ft h eH N M T
inhibitors SKF91488 (SKF), tacrine (Tac), diphenhydramine (Dip) and chlorpromazine (Chl) on PfPMT activity. (B) Effect of chloroquine (CQ),
quinacrine (QC), quinidine (QD) and quinine (QN) on PfPMT activity. The data are the means +/- S.D. for three independent experiments.
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Page 9 of 16diphenhydramine and chlorpromazine [37-39] had no
effect on PfPMT, suggesting that the interaction
between PfPMT and AQ is unique.
Amodiaquine is a structural analog of CQ. Analysis of
uncomplicated falciparum malaria cases in Africa sug-
gested that AQ is more effective in clearing parasites,
including CQ resistant strains, and resulted in better
clinical recovery compared to CQ [40-42]. Amodiaquine
is used mostly in combination therapy with artesunate
and sulfadoxine-pyrimethamine to treat malaria
infections, especially those caused by CQ resistant
strains [43]. Following oral administration, AQ is
detected in the plasma between 30 min and 8 h, but is
rapidly converted to desethylamodiaquine (AQm) with a
peak plasma concentration of 181 ± 26 ng ml
-1 [44]. In
the liver AQ is converted to AQm by the polymorphic
P450 isoform CYP2C8 [45]. Up to 96 hours after admin-
istration, AQm could be detected in the plasma, a prop-
erty that made AQ an ideal compound in combination
therapy [46]. In vitro both AQ and AQm inhibit parasite
Figure 6 Amodiaquine inhibits PfPMT function in yeast. Growth curves of wild-type (BY4741-pYes2.1) (A) and pem1Δpem2Δ-PfPMT (B) strains
grown in minimal medium containing 4% galactose and 100 μM ethanolamine in the presence of 0 μM (1), 10 μM (2), 50 μM (3), or 100 μM (4)
AQ. (C-E) Growth curves of wild-type (BY4741-pYes2.1) (C), pem1Δpem2Δ-pYes2.1 (D) and pem1Δpem2Δ-PfPMT (E) yeast strains grown in minimal
medium containing 4% galactose and 2 mM ethanolamine in the presence of 0 μM AQ (5), 200 μM AQ (6), 200 μM AQ and 1 mM choline (7),
or 1 mM choline (8).
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Page 10 of 16intraerythrocytic growth with IC50 values of 18.2 and
67.5 nM, respectively [47]. The modes of action of AQ
and AQm are unknown. Field studies suggest that low
levels of resistance to AQ associate with mutations in
the PfCRT and PfMDR1 genes, whereas high AQ resis-
tance involves unknown mechanisms [48]. These find-
i n g ss u g g e s tt h a tA Qm i g h thave CQ like properties in
the food vacuole as well as novel activities that remain
to be elucidated. Interestingly, whereas AQ inhibited
PfPMT activity, CQ did not. PfPMT activity was also
not affected by the antimalarials quinine, quinidine and
quinacrine at concentrations as high as 200 μM. The
specificity of inhibition by AQ was demonstrated in vivo
by using yeast as a surrogate system. In yeast, the
growth of mutants that rely on PfPMT for survival was
dramatically altered in the presence of this compound.
Consistent with this phenotype, the synthesis of PtdCho
in these complemented cells was strongly inhibited by
AQ. Surprisingly, the amplitude of inhibition of pem1Δ-
pem2Δ+PfPMT cells by AQ was dependent on the
Figure 7 Amodiaquine reduced PfPMT-dependent PtdCho levels in yeast. (A) Phospholipid analysis of pem1Δpem2Δ-pYes2.1 and
pem1Δpem2Δ-PfPMT strains grown in minimal medium containing 4% galactose and 2 mM ethanolamine. The lipids were extracted, separated
by 2-D TLC and stained with iodine vapor. (B) Each lipid was recovered from the TLC plate and quantified by measuring phosphorous. The
graph is the percentage of total lipid phosphorous in each lipid fraction. PtdCho-phosphatidylcholine; PtdEtn- phosphatidylethanolamine; PtdSer-
phosphatidylserine; PtdIns- phosphatidylinositol. The data are represented as the means +/- S.D. of three independent experiments.
Figure 8 Prediction of amodiaquine-interacting residues on PfPMT using HNMT structure. (A) Molecular surface representation of HNMT.
Red solvent-accessible surfaces identify invariant residues between HNMT and PfPMT. Phe190 is colored in orange. Two AQ molecules are
shown as stick with the carbon atoms depicted in cyan, nitrogen in blue, oxygen in red, and chlorine in green. (B) The Ca trace of HNMT in a
similar orientation as (A). The AQ-interacting residues are shown as stick forms. The HNMT residues, corresponding to the nine residues of PfPMT
whose chemical shifts are perturbed in response to AQ binding, are shown in green. Figures were prepared by using Pymol [56].
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This is likely due to the fact that these complemented
cells grow faster on medium containing high concentra-
tions of ethanolamine as a result of increased substrate
availability for PfPMT.
Recent genetic studies have shown that PfPMT plays
an important function during P. falciparum intraery-
throcytic development, multiplication and survival [13],
and an essential role in sexual differentiation (Bobenchik
et al., unpublished data). Interestingly, silencing of the
A. thaliana PEAMT results in multiple morphological
phenotypes, including pale-green leaves, early senes-
cence, temperature-sensitive male sterility and increased
sensitivity to salts [49]. Furthermore, characterization of
an A. thaliana mutant with the T-DNA inserted at the
At3g18000 locus (XIPOTL1), which encodes PEAMT
revealed severe alterations in root developmental and
induces cell death in root epidermal cells [50]. In C. ele-
gans, studies aimed at silencing the PEAMT genes
PMT-1 and PMT-2 demonstrated an essential function
of these genes in worm, growth, development and survi-
val [8,11]. Altogether, these genetic studies validate
PEAMT enzymes as possible targets for the develop-
ment of inhibitors that could be used for the treatment
of specific human and veterinary protozoa and nema-
tode related infections as well as in agriculture.
P. falciparum parasites lacking PfPMT were, however,
equally sensitive to AQ as wild-type parasites in medium
containing choline. This result suggests that PfPMT is
not the sole target of AQ in choline-containing medium.
Our finding that AQ inhibits PfPMT activity, and the
fact that this compound also inhibits other eukaryotic
Figure 9 NMR analysis of PfPMT-amodiaquine interaction. The glycine region of the 1H-15N HSQC spectra of PfPMT (0.3 mM), titrated with
AQ (A) or CQ (B). The different colors indicate the inhibitor concentrations as follows: red- no inhibitor, orange- 1:4, yellow- 1:2, green- 1:1, blue-
2:1, violet- 3:1, black- 10:1. (C and D) Inhibitor titration plots for Gly32 and Gly68 (derived from A and B) showing the difference in binding
between AQ and CQ. The overlay of the full HSQC spectrum in the absence or presence of AQ is shown in Additional File 1, Fig. S1.
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larial activity by targeting several parasite methyltrans-
ferases. Several studies have suggested that
aminoquinolines may exert their antimalarial activity by
interfering with biological functions other than heme
detoxification in the digestive vacuole. Famin and Gins-
burg reported inhibition of parasite’s 6-phosphogluco-
nate dehydrogenase by CQ [51]. Sharma and Mishra
reported inhibition of parasite’s tyrosine kinase by this
compound [52]. Recently, CQ was reported to inhibit
vesicular trafficking within the parasite [53], and to
induce proteome oxidative damage [54]. More recent
studies aimed at investigating the stage specificity of CQ
and comparing the effect of continuous vs bolus dosing
on P. falciparum strains revealed that rings (prior to the
formation of the digestive vacuole) and schizont stage
parasites (after hemoglobin degradation and heme
detoxification activities have plateaued) were equally
sensitive to this compound [55]. The bolus dosing con-
centrations of CQ used by Gligorijevic and colleagues
a r ei nt h er a n g eo ft h ec o m p o u n d ’sp e a kp l a s m ac o n -
centration (low micromolar range) [55]. Together these
studies suggest that heme detoxification, although
important, is unlikely to be the only target of CQ.
Although, the stage specificity and the effect of bolus
dosing of AQ on P. falciparum have not been investi-
gated, our results indicate that at its peak plasma con-
centration, AQ is likely to inhibit PfPMT and possibly
other parasite methyltransferases. Future studies will
aim to identify Plasmodium methyltransferases inhibited
by AQ and to characterize the mechanism of sensitivity
and resistance to AQ. From a chemistry standpoint, AQ
represents an excellent lead compound for the rational
design of better inhibitors of PfPMT and other parasite
methyltransferases as well as plant and nematode PMTs.
Horton and coworkers have previously shown that AQ
acts both as a competitive and a noncompetitive inhibi-
tor of human HNMT [31]. The crystal structure of the
HNMT-AQ complex [31] revealed that one AQ mole-
cule binds to the histamine-binding site (Site 1), while
the second one tucks into an adjacent pocket on the
outer surface of the protein (Site 2) (Fig. 8A). Both qui-
noline rings fit into a sandwich-like structure formed by
the aromatic side chains of Tyr15 and Phe19, and
Phe190 and Tyr198, respectively (Fig. 8B). The side
chains of Trp183 and Phe243 also contribute to the sta-
bilization of the branched alkylamino tail of the AQ in
the histamine-binding site [31]. It should be noted that
the branch structure of the second AQ is disordered in
the outer-surface pocket, suggesting a weaker binding
interaction. The strong hydrophobic interactions
between AQ and the aromatic side chains of the enzyme
have been proposed to account for the affinity and spe-
cificity of the inhibitor for HNMT [31]. Sequence
alignment analysis of HNMT and PfPMT shows that
Tyr15, Trp183, and Phe243 are conserved in PfPMT,
while Phe190 is substituted by tyrosine (Fig. 8B and
Additional file 2, Fig. S2). This structural conservation is
significant, as the two proteins have an overall 14% pair-
wise sequence identity. The majority of the other invar-
iant residues are within the classic SAM-dependent
methyltransferase fold in HNMT (Fig. 8B and Addi-
tional file 2, Fig. S2). Our inhibition studies revealed
that whereas AQ inhibited PfPMT activity, CQ did not.
PfPMT activity was also not affected by the aminoqui-
nolines, quinine, quinidine and quinacrine at concentra-
t i o n sa sh i g ha s2 0 0μM, or by the histamine
methyltransferase inhibitors SKF91488, diphenhydra-
mine and tacrine at concentrations as high as 100 μM.
U n l i k eA Q ,d i p h e n h y d r a m i n ea n dt a c r i n eh a v eb e e n
shown to interact only with Site 1 of HNMT. If this
property is also valid in the case of PfPMT, it may
account for the difference in inhibition of PfPMT activ-
ity between AQ and other aminoquinolines. The NMR
studies reported here confirmed the site-specific binding
of AQ to PfPMT, as less than 10% of residues in PfPMT
showed a significant change in chemical shift in the pre-
sence of the compound. Nine of these residues have
thus far been assigned. Six of those (corresponding to
Glu28, Ser26, Ala63, Glu65, Ile66 and Met36 in HNMT)
are proximal to the histamine-binding site (Site 1), while
the 7th (Leu261 in HNMT) is proximal to Site 2. The
8th (Cys196 in HNMT) is located between the two sites.
The last residue (Leu108 in HNMT) is further from Site
1, but is proximal to residues in contact with this site,
and could be a relayed effect. The three residues (Gly68,
Gly32 and Gly40 corresponding to Glu65, Glu28 and
Met36 in HNMT) with the largest shift changes are clo-
sest to site 1. The binding of AQ to the free enzyme
suggests that the inhibition is not uncompetitive, i.e. via
binding to the enzyme-substrate complex, and therefore
either competitive or noncompetitive. The NMR experi-
ments at this stage do not definitively reveal whether
AQ binds competitively to the substrate binding site.
NMR studies to determine the structure of PfPMT
alone and in combination with AQ are underway. They
will address the question of noncompetitive vs. competi-
tive inhibition, and should shed new light on the inter-
action between the enzyme and the inhibitor. However,
based on our preliminary assignment of two of the nine
assigned residues, Gly32 and Gly68, and the known
structure of HNMT, we can postulate a structural
hypothesis consistent with the NMR results for Gly32
and Gly68. Gly32 and Gly68 of PfPMT correspond to
Glu28 and Glu65 of HNMT (Fig. 9). Glu28 lies at the
bottom of the cleft comprising site 1 of HNMT. Glu65
also lines the surface of the cleft, closer to the enzyme
surface. The similarity of the chemical shift perturbation
Bobenchik et al. BMC Biochemistry 2010, 11:4
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Page 13 of 16curves (to within the experimental uncertainty of ~
0.006 ppm) for Gly32 and Gly68 is thus consistent with
binding at site 1. Despite the low sequence homology
between PfPMT and HNMT, these data suggest that
PfPMT and HNMT nevertheless exhibit structural
homology, and are consistent with two AQ binding
sites. The proximity of the two binding sites suggests
that titration data might reflect coupling between sites.
Indeed, we do not observe partitioning of the titration
data into two distinct classes, as would be expected for
independent binding sites.
Conclusions
The enzyme-coupled assay adapted for PfPMT is a sim-
ple and reliable method for measuring PfPMT activity
and screening for specific inhibitors of this enzyme. The
identification of AQ as an inhibitor of PfPMT may help
in the future design of compounds that specifically inhi-
bit this enzyme and possibly other PMTs.
Additional file 1: Fig. S1. Overlay of the full
1H-
15N HSQC spectra of
PfPMT in the absence (red) or presence of 0.06 (orange), 0.12 (yellow),
0.25 (green), 0.5 (blue) and 1 mM (purple) of AQ.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2091-11-4-
S1.ppt]
Additional file 2: Fig. S2. Sequence alignment of HNMT and PfPMT.
Residues that are identical, conserved, and semi-conserved are indicated
by asterisk, colon, and period, respectively. The AQ-interacting residues
are colored as in Fig. 8B. Phe19 and Tyr198 of HNMT and their
corresponding residues in PfPMT are shown in italics and bold.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2091-11-4-
S2.ppt]
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